. "Pioglitazon is an important antidiabeticum from the group of so-called insulin sensitizors \u2013 stimulators of metabolic core receptors PPAR-g. When administered in 15mg (or 30 mg) once a day, a reduction of glycohemaglobin by 1 \u2013 1.5 % is achieved. The effect appears gradually in the course of one month and gets higher even after several months of treatment. Pioglitazon is indicated for treatment of type 2 diabetes"@en . "11150" . . "\u0160mahelov\u00E1, Alena" . "Remedia" . "Pioglitazon"@en . "Pioglitazon"@cs . . "2"^^ . "210;213" . "Pioglitazon"@en . . "Pioglitazon"@en . "RIV/00216208:11150/06:00005073" . . "Pioglitazon je v\u00FDznamn\u00E9 antidiabetikum ze skupiny tzv. inzulinov\u00FDch senzitiz\u00E9r\u016F \u2013 stimul\u00E1tor\u016F metabolick\u00FDch jadern\u00FDch receptor\u016F PPAR-g. P\u0159i d\u00E1vkov\u00E1n\u00ED jednou denn\u011B 15 mg, resp. 30 mg se dosahuje sn\u00ED\u017Een\u00ED glykovan\u00E9ho hemoglobinu o 1\u20131,5 %. \u00DA\u010Dinek nastupuje postupn\u011B b\u011Bhem m\u011Bs\u00EDce a zvy\u0161uje se i po n\u011Bkolika m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby. Pioglitazon je indikov\u00E1n v l\u00E9\u010Db\u011B diabetu 2. typu." . "Pioglitazon je v\u00FDznamn\u00E9 antidiabetikum ze skupiny tzv. inzulinov\u00FDch senzitiz\u00E9r\u016F \u2013 stimul\u00E1tor\u016F metabolick\u00FDch jadern\u00FDch receptor\u016F PPAR-g. P\u0159i d\u00E1vkov\u00E1n\u00ED jednou denn\u011B 15 mg, resp. 30 mg se dosahuje sn\u00ED\u017Een\u00ED glykovan\u00E9ho hemoglobinu o 1\u20131,5 %. \u00DA\u010Dinek nastupuje postupn\u011B b\u011Bhem m\u011Bs\u00EDce a zvy\u0161uje se i po n\u011Bkolika m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby. Pioglitazon je indikov\u00E1n v l\u00E9\u010Db\u011B diabetu 2. typu."@cs . . "441390" . "16" . . . "Pioglitazon" . . "[80D1A5B78FF3]" . "0862-8947" . "RIV/00216208:11150/06:00005073!RIV08-MSM-11150___" . "CZ - \u010Cesk\u00E1 republika" . . "Pioglitazon" . . . "Pioglitazon"@cs . "2" . "S" . "4"^^ . "1"^^ .